Trial · NCT01270711
Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
NCT01270711, Completed, Pfizer; results first posted 2014-03-24
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE). Trials, record NCT01270711. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01270711
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
- NCT number
- NCT01270711
- Status
- Completed
- Enrollment
- 22,014 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Parkinson's Disease, Hyperprolactinemia
- Interventions
- Study Drug
- First posted
- 2011-01-05
- Last updated
- 2014-05-02
- Results first posted
- 2014-03-24
- Limitations and caveats
Results not reported for Year 2012 (Year 7) since several databases did not contribute data for Year 7 and amount of person-time of follow-up dropped in all databases. Designation of primary and secondary endpoints was based on study team's input.
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Cabergoline Prescriptions by Database and Indication: Year 1 | Year 1 (Year 2006) | Cabergoline prescriptions were stratified by indications per year. Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication. |
| Primary | Number of Cabergoline Prescriptions by Database and Indication: Year 2 | Year 2 (Year 2007) | Cabergoline prescriptions were stratified by indications per year. Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication. |
| Primary | Number of Cabergoline Prescriptions by Database and Indication: Year 3 | Year 3 (Year 2008) | Cabergoline prescriptions were stratified by indications per year. Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication. |
| Primary | Number of Cabergoline Prescriptions by Database and Indication: Year 4 | Year 4 (Year 2009) | Cabergoline prescriptions were stratified by indications per year. Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication. |
| Primary | Number of Cabergoline Prescriptions by Database and Indication: Year 5 | Year 5 (Year 2010) | Cabergoline prescriptions were stratified by indications per year. Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication. |
| Primary | Number of Cabergoline Prescriptions by Database and Indication: Year 6 | Year 6 (Year 2011) | Cabergoline prescriptions were stratified by indications per year. Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication. |
| Primary | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 1 | Year 1 (Year 2006) | Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy. Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy. Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported. |
| Primary | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 2 | Year 2 (Year 2007) | Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy. Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy. Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported. |
| Primary | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 3 | Year 3 (Year 2008) | Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy. Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy. Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported. |
| Primary | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 4 | Year 4 (Year 2009) | Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy. Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy. Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Cabergoline Prescriptions by Database and Indication: Year 1 | Year 1 (Year 2006) | Study population included all participants who were registered in one of the databases and were treated with cabergoline during the study period. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | prescriptions | NUMBER |
| PRIMARY | Number of Cabergoline Prescriptions by Database and Indication: Year 2 | Year 2 (Year 2007) | Study population included all participants who were registered in one of the databases and were treated with cabergoline during the study period. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | prescriptions | NUMBER |
| PRIMARY | Number of Cabergoline Prescriptions by Database and Indication: Year 3 | Year 3 (Year 2008) | Study population included all participants who were registered in one of the databases and were treated with cabergoline during the study period. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | prescriptions | NUMBER |
| PRIMARY | Number of Cabergoline Prescriptions by Database and Indication: Year 4 | Year 4 (Year 2009) | Study population included all participants who were registered in one of the databases and were treated with cabergoline during the study period. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | prescriptions | NUMBER |
| PRIMARY | Number of Cabergoline Prescriptions by Database and Indication: Year 5 | Year 5 (Year 2010) | Study population included all participants who were registered in one of the databases and were treated with cabergoline during the study period. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | prescriptions | NUMBER |
| PRIMARY | Number of Cabergoline Prescriptions by Database and Indication: Year 6 | Year 6 (Year 2011) | Study population included all participants who were registered in one of the databases and were treated with cabergoline during the study period. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | prescriptions | NUMBER |
| PRIMARY | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 1 | Year 1 (Year 2006) | Study population: participants registered in one of databases and were treated with cabergoline during study period. Data not reported for IPCI and PHARMO databases because no information was retrieved for second-line prescriptions of cabergoline for Parkinson's disease. 'N' (number of participants analyzed)=participants evaluable for this measure. | percentage of prescriptions | NUMBER |
| PRIMARY | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 2 | Year 2 (Year 2007) | Study population: participants registered in one of databases and were treated with cabergoline during study period. Data not reported for IPCI and PHARMO databases because no information was retrieved for second-line prescriptions of cabergoline for Parkinson's disease. 'N' (number of participants analyzed)=participants evaluable for this measure. | percentage of prescriptions | NUMBER |
| PRIMARY | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 3 | Year 3 (Year 2008) | Study population: participants registered in one of databases and were treated with cabergoline during study period. Data not reported for IPCI and PHARMO databases because no information was retrieved for second-line prescriptions of cabergoline for Parkinson's disease. 'N' (number of participants analyzed)=participants evaluable for this measure. | percentage of prescriptions | NUMBER |
| PRIMARY | Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 4 | Year 4 (Year 2009) | Study population: participants registered in one of databases and were treated with cabergoline during study period. Data not reported for IPCI and PHARMO databases because no information was retrieved for second-line prescriptions of cabergoline for Parkinson's disease. 'N' (number of participants analyzed)=participants evaluable for this measure. | percentage of prescriptions | NUMBER |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 outcomesResults by group117
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | Aarhus [Part 1] | G02CB03 | 17 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | HSD [Part 1] | G02CB03 | 1782 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | IPCI [Part 1] | G02CB03 | 6 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | PHARMO [Part 1] | G02CB03 | 293 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | THIN [Part 1] | G02CB03 | 198 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | Aarhus [Part 1] | N04BC06 | 87 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | HSD [Part 1] | N04BC06 | 1483 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | IPCI [Part 1] | N04BC06 | 0 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | PHARMO [Part 1] | N04BC06 | 0 | prescriptions | |
| Number of Cabergoline Prescriptions by Database and Indication: Year 1 | THIN [Part 1] | N04BC06 | 577 | prescriptions |
1 to 10 of 117Source ClinicalTrials.gov
See all 117 results by groupParticipant flow48
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1: Compliance | STARTED | Aarhus [Part 1] | 7,537 | |
| Part 1: Compliance | STARTED | HSD [Part 1] | 6,580 | |
| Part 1: Compliance | STARTED | IPCI [Part 1] | 326 | |
| Part 1: Compliance | STARTED | PHARMO [Part 1] | 5,486 | |
| Part 1: Compliance | STARTED | THIN [Part 1] | 2,024 | |
| Part 1: Compliance | STARTED | Cabergoline in Pre-SPC Change Period [Part 2] | 0 | |
| Part 1: Compliance | STARTED | Cabergoline in Post- SPC Change Period [Part 2] | 0 | |
| Part 1: Compliance | STARTED | Cabergoline in Cross-SPC Change Period [Part 2] | 0 | |
| Part 1: Compliance | COMPLETED | Aarhus [Part 1] | 7,537 | |
| Part 1: Compliance | COMPLETED | HSD [Part 1] | 6,580 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals24
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Aarhus [Part 1] | ||
| Total, all-cause mortality | HSD [Part 1] | ||
| Total, all-cause mortality | IPCI [Part 1] | ||
| Total, all-cause mortality | PHARMO [Part 1] | ||
| Total, all-cause mortality | THIN [Part 1] | ||
| Total, all-cause mortality | Cabergoline in Pre-SPC Change Period [Part 2] | ||
| Total, all-cause mortality | Cabergoline in Post- SPC Change Period [Part 2] | ||
| Total, all-cause mortality | Cabergoline in Cross-SPC Change Period [Part 2] | ||
| Total, other adverse events | Aarhus [Part 1] | 0 | 0 |
| Total, other adverse events | HSD [Part 1] | 0 | 0 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01270711
GET https://conductscience.org/api/trials/v1/NCT01270711/registered?page=2